By Dr. Ari Weitzner A study compared Xalatan/Timolol combination to Travatan and Lumigan/Timoptic combinations. The Lumigan combination lowered the IOP the most (1.7 more than Xalatan, 0.7 more than Travatan). I dread getting an earful from the drug rep…
New Clinical Data On Meriva Show Eye Inflammations Reduction
A new clinical study published in Clinical Ophthalmology shows that Meriva, an Indena proprietary complex of curcumin with soy phosphatidylcholine, can play an important role in the adjunctive therapy of recurrent anterior uveitis (RAU), the most com…
Novartis Third-Quarter Net Rises on Lucentis, Exforge
Novartis AG indicated Alcon Inc. shareholders should take another look at its $11.5 billion buyout offer now that an increase in the Swiss drugmakers share price and a rally in the franc have lifted the value of the bid. Novartis, which owns 77 perce…
Alcon 3Q profit falls on Novartis deal costs
Alcon Inc., which makes treatments for glaucoma and eye infections, said Wednesday its third-quarter net income fell 13 percent on costs related to its majority takeover by fellow Swiss drugmaker Novartis SA. Still the results topped analysts’ expect…
Should We Be Administering Besivance or Azasite Via DuraSite After Phaco?
By Dr. Ari WeitznerAn article in AJO compared Besivance, Azasite (both using DuraSite vehicle) and Cipro when injected into rabbit eye anterior chambers. It seems the Durasite blocks the trabecular meshwork and may be toxic. The authors advise not using these drops after clear corneal surgery unless a suture is placed. I don’t know anybody […]
Abbott’s 3Q drug sales up 22 percent, net income drops on restructuring, recall costs
Abbott Laboratories, a maker of drugs and medical devices, fell after it reported third-quarter sales that missed analysts estimates. The shares dropped 45 cents, or less than 1 percent, to $52.42 at 4:03 p.m. in New York Stock Exchange composite tra…